About Exelead
Exelead is a Healthcare company based in Indianapolis (United States) founded in 2016, and was acquired by Merck in January 2022. Small-batch liposomal and pegylated formulations are developed and manufactured. Exelead offers products and services including Lipid Nanoparticle CDMO and mRNA Development and Manufacturing. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Its competitors include Exela Pharma, August Bioservices and ApiJect; 3 of its 3 listed competitors have raised funding.
Company details
Exelead, a wholly owned subsidiary of Leadiant Biosciences, is a contract manufacturer of liquid injectables and specializes in the development and manufacturing of complex liposomal and pegylated formulations. The company has capabilities to manufacture for both clinical and commercial applications. Their clientele includes companies ranging from small, venture startups to medium size companies. The company is capable of handling small batches and formulations which are meant for rare disease and small populations. Their clientele includes Teva, Shire (Exelead is the CMO for Oncaspar), Horizon Pharma and Aradigm. The company also has an in-house portfolio which includes Adagen (a pegademase bovine injection), DepoCyt (cytarabine liposome injection), and Abelcet (amphotericin B lipid complex injection).
- Headquarters Indianapolis, United States
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website exeleadbiopharma.com
- Social LinkedIn
- Acquired by Merck (Jan 2022)
Products & Services of Exelead
Exelead offers a comprehensive portfolio of products and services, including Lipid Nanoparticle CDMO and mRNA Development and Manufacturing.
Service for developing and manufacturing lipid nanoparticles for drug delivery
Provides synthesis, purification, and formulation for mRNA products
Investors in Exelead
Exelead has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Merck.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Merck is engaged in science and technology solutions globally. | 1668 | merckgroup.com | Darmstadt, Germany |
Investor details for Exelead
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Exelead
5 people are tracked at Exelead (5 in team).
| Name | Role | Group |
|---|---|---|
Glenda Ventura | Manufacturing Engineer, Packaging | Team |
Evan Elliott | Process Engineer | Team |
Larry Beiter | Process Engineering And Development | Team |
Eric Bellamy | Quality Engineer For Packaging/artwork | Team |
Tracey Froggatt | Sr. Quality Assurance Auditor | Team |
Complete people profiles for Exelead
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Exelead
2 dated milestones of Exelead across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Exelead is founded.
- Exit Acquired by Merck.
Competitors of Exelead
Exelead has 3 listed competitors in our database, 3 of them funded. They include Exela Pharma, August Bioservices and ApiJect.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| exelapharma.com | 2005 | Lenoir, United States | $7.09M | 247 | Sterile injectable pharmaceuticals are manufactured alongside CDMO services. | |
| augustbio.com | 2017 | Nashville, United States | $88.6M | 86 | Diversified research services for clinical solutions are offered. | |
| apiject.com | 2015 | Stamford, United States | $111M | Medicine injectors are manufactured by ApiJect for medical applications. |
Detailed competitors of Exelead
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Exelead (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Exelead
Complete news archive for Exelead
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Exelead
Exelead was founded in 2016.
Exelead is headquartered in Indianapolis, United States. It is registered at Indianapolis, Indiana, United States.
Exelead, a wholly owned subsidiary of Leadiant Biosciences, is a contract manufacturer of liquid injectables and specializes in the development and manufacturing of complex liposomal and pegylated formulations. The company has capabilities to manufacture for both clinical and commercial applications. Their clientele includes companies ranging from small, venture startups to medium size companies. The company is capable of handling small batches and formulations which are meant for rare disease and small populations. Their clientele includes Teva, Shire (Exelead is the CMO for Oncaspar), Horizon Pharma and Aradigm. The company also has an in-house portfolio which includes Adagen (a pegademase bovine injection), DepoCyt (cytarabine liposome injection), and Abelcet (amphotericin B lipid complex injection).
Exelead's top competitors include Exela Pharma, August Bioservices and ApiJect.
Exelead offers Lipid Nanoparticle CDMO and mRNA Development and Manufacturing.
Exelead has 1 investor. Key investors include Merck.
Yes. Exelead was acquired by Merck in January 2022.